Orexo
13,72 SEK -2%Vær den første som følger denne virksomhed
Orexo is a Swedish pharmaceutical company that develops medicines based on proprietary formulation technologies that meet major medical needs. In the US market, Orexo offers treatment solutions for patients suffering from opioid addiction and related diseases. Products targeting other therapeutic areas are developed and commercialized worldwide in collaboration with partners. The head office, where the research and development work is conducted, is located in Uppsala.
Omsætning
638,8 mio.
EBIT %
-17,14 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
ORX
Daglig lav / høj pris
13,3 / 14
SEK
Markedsværdi
476,23 mio. SEK
Aktieomsætning
228,03 t SEK
Volumen
17 t
Seneste videoer
Finanskalender
Delårsrapport
24.10.2024
Årsrapport
06.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Novo A/S | 27,8 % | 27,8 % |
Avanza Pension | 6,8 % | 6,8 % |
Arbejdsmarkedets Tillaegspension (ATP) | 5,1 % | 5,1 % |
Anders Walldov direct and indirect | 4,6 % | 4,6 % |
Swedbank Insurance | 2,8 % | 2,8 % |
Nordnet Pension Insurance | 1,7 % | 1,7 % |
Stefan Hansson | 1,3 % | 1,3 % |
Håkan Lejonkula | 1,2 % | 1,2 % |
Christer Nyström | 0,7 % | 0,7 % |
Eccenovo AB | 0,7 % | 0,7 % |
ViserAlle indholdstyper
Orexo, Audiocast with teleconference, Q3'24
Orexo to participate in Pareto Securities' 15th Annual Healthcare Conference 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools